|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zang X, Thompson RH, Al-Ahmadie HA, Serio
AM, Reuter VE, Eastham JA, Scardino PT, Sharma P and Allison JP:
B7-H3 and B7x are highly expressed in human prostate cancer and
associated with disease spread and poor outcome. Proc Natl Acad Sci
USA. 104:19458–19463. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tsiaousidou A, Lambropoulou M,
Chatzitheoklitos E, Tripsianis G, Tsompanidou C, Simopoulos C and
Tsaroucha AK: B7H4, HSP27 and DJ-1 molecular markers as prognostic
factors in pancreatic cancer. Pancreatology. 13:564–569. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao X, Li DC, Zhu XG, Gan WJ, Li Z, Xiong
F, Zhang ZX, Zhang GB, Zhang XG and Zhao H: B7-H3 overexpression in
pancreatic cancer promotes tumor progression. Int J Mol Med.
31:283–291. 2013.
|
|
5
|
Sun Y, Wang Y, Zhao J, Gu M, Giscombe R,
Lefvert AK and Wang X: B7-H3 and B7-H4 expression in non-small-cell
lung cancer. Lung Cancer. 53:143–151. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schneider T, Hoffmann H, Dienemann H,
Schnabel PA, Enk AH, Ring S and Mahnke K: Non-small cell lung
cancer induces an immunosuppressive phenotype of dendritic cells in
tumor microenvironment by upregulating B7-H3. J Thorac Oncol.
6:1162–1168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Krambeck AE, Thompson RH, Dong H, Lohse
CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC and Kwon
ED: B7-H4 expression in renal cell carcinoma and tumor vasculature:
Associations with cancer progression and survival. Proc Natl Acad
Sci USA. 103:10391–10396. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Crispen PL, Sheinin Y, Roth TJ, Lohse CM,
Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich
BC, et al: Tumor cell and tumor vasculature expression of B7-H3
predict survival in clear cell renal cell carcinoma. Clin Cancer
Res. 14:5150–5157. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Simon I, Zhuo S, Corral L, Diamandis EP,
Sarno MJ, Wolfert RL and Kim NW: B7-h4 is a novel membrane-bound
protein and a candidate serum and tissue biomarker for ovarian
cancer. Cancer Res. 66:1570–1575. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zang X, Sullivan PS, Soslow RA, Waitz R,
Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, et al:
Tumor associated endothelial expression of B7-H3 predicts survival
in ovarian carcinomas. Mod Pathol. 23:1104–1112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu W, Shibata K, Koya Y, Kajiyama H,
Senga T, Yamashita M and Kikkawa F: B7-H4 overexpression correlates
with a poor prognosis for cervical cancer patients. Mol Clin Oncol.
2:219–225. 2014.PubMed/NCBI
|
|
12
|
Mailloux AW and Young MR: Regulatory
T-cell trafficking: From thymic development to tumor-induced immune
suppression. Crit Rev Immunol. 30:435–447. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu X, Liu J, Li H, Li W, Wang X, Ma J,
Tong Q, Wu K and Wang G: Conversion of intratumoral regulatory T
cells by human gastric cancer cells is dependent on transforming
growth factor-β1. J Surg Oncol. 104:571–577. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Woo EY, Chu CS, Goletz TJ, Schlienger K,
Yeh H, Coukos G, Rubin SC, Kaiser LR and June CH: Regulatory
CD4(+)CD25(+) T cells in tumors from patients with early-stage
non-small cell lung cancer and late-stage ovarian cancer. Cancer
Res. 61:4766–4772. 2001.PubMed/NCBI
|
|
15
|
Wang HY and Wang RF: Regulatory T cells
and cancer. Curr Opin Immunol. 19:217–223. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hinz S, Pagerols-Raluy L, Oberg HH,
Ammerpohl O, Grüssel S, Sipos B, Grützmann R, Pilarsky C,
Ungefroren H, Saeger HD, et al: Foxp3 expression in pancreatic
carcinoma cells as a novel mechanism of immune evasion in cancer.
Cancer Res. 67:8344–8350. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Liu R, Li W, Chen C, Katoh H, Chen
GY, McNally B, Lin L, Zhou P, Zuo T, et al: Somatic single hits
inactivate the X-linked tumor suppressor FOXP3 in the prostate.
Cancer Cell. 16:336–346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang LH, Su L and Wang JT: Correlation
between elevated FOXP3 expression and increased lymph node
metastasis of gastric cancer. Chin Med J (Engl). 123:3545–3549.
2010.
|
|
19
|
Zang X, Loke P, Kim J, Murphy K, Waitz R
and Allison JP: B7x: A widely expressed B7 family member that
inhibits T cell activation. Proc Natl Acad Sci USA.
100:10388–10392. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sica GL, Choi IH, Zhu G, Tamada K, Wang
SD, Tamura H, Chapoval AI, Flies DB, Bajorath J and Chen L: B7-H4,
a molecule of the B7 family, negatively regulates T cell immunity.
Immunity. 18:849–861. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Prasad DV, Richards S, Mai XM and Dong C:
B7S1, a novel B7 family member that negatively regulates T cell
activation. Immunity. 18:863–873. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang X, Wang T, Xu M, Xiao L, Luo Y, Huang
W, Zhang Y and Geng W: B7-H4 overexpression impairs the immune
response of T cells in human cervical carcinomas. Hum Immunol.
75:1203–1209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kryczek I, Wei S, Zhu G, Myers L, Mottram
P, Cheng P, Chen L, Coukos G and Zou W: Relationship between B7-H4,
regulatory T cells, and patient outcome in human ovarian carcinoma.
Cancer Res. 67:8900–8905. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kryczek I, Zou L, Rodriguez P, Zhu G, Wei
S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, et al: B7-H4
expression identifies a novel suppressive macrophage population in
human ovarian carcinoma. J Exp Med. 203:871–881. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Galazka K, Opławski M, Windorbska W,
Skret-Magierlo J, Koper K, Basta P, Mach P, Dutch-Wicherek M, Mazur
A and Wicherek L: The immunohistochemical analysis of antigens such
as RCAS1 and B7H4 in the cervical cancer nest and within the
fibroblasts and macrophages infiltrating the cancer
microenvironment. Am J Reprod Immunol. 68:85–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamato I, Sho M, Nomi T, Akahori T,
Shimada K, Hotta K, Kanehiro H, Konishi N, Yagita H and Nakajima Y:
Clinical importance of B7-H3 expression in human pancreatic cancer.
Br J Cancer. 101:1709–1716. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Arigami T, Narita N, Mizuno R, Nguyen L,
Ye X, Chung A, Giuliano AE and Hoon DS: B7-h3 ligand expression by
primary breast cancer and associated with regional nodal
metastasis. Ann Surg. 252:1044–1051. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun TW, Gao Q, Qiu SJ, Zhou J, Wang XY, Yi
Y, Shi JY, Xu YF, Shi YH, Song K, et al: B7-H3 is expressed in
human hepatocellular carcinoma and is associated with tumor
aggressiveness and postoperative recurrence. Cancer Immunol
Immunother. 61:2171–2182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Roth TJ, Sheinin Y, Lohse CM, Kuntz SM,
Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML,
et al: B7-H3 ligand expression by prostate cancer: A novel marker
of prognosis and potential target for therapy. Cancer Res.
67:7893–7900. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Quandt D, Fiedler E, Boettcher D, Marsch
WC and Seliger B: B7-h4 expression in human melanoma: Its
association with patients' survival and antitumor immune response.
Clin Cancer Res. 17:3100–3111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boland JM, Kwon ED, Harrington SM,
Wampfler JA, Tang H, Yang P and Aubry MC: Tumor B7-H1 and B7-H3
expression in squamous cell carcinoma of the lung. Clin Lung
Cancer. 14:157–163. 2013. View Article : Google Scholar
|
|
32
|
Strauss L, Bergmann C, Szczepanski M,
Gooding W, Johnson JT and Whiteside TL: A unique subset of
CD4+CD25highFoxp3+ T cells
secreting interleukin-10 and transforming growth factor-beta1
mediates suppression in the tumor microenvironment. Clin Cancer
Res. 13:4345–4354. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Geng Y, Wang H, Lu C, Li Q, Xu B, Jiang J
and Wu C: Expression of costimulatory molecules B7-H1, B7-H4 and
Foxp3+ Tregs in gastric cancer and its clinical
significance. Int J Clin Oncol. 20:273–281. 2015. View Article : Google Scholar
|
|
34
|
Luo Q, Zhang S, Wei H, Pang X and Zhang H:
Roles of Foxp3 in the occurrence and development of cervical
cancer. Int J Clin Exp Pathol. 8:8717–8730. 2015.PubMed/NCBI
|
|
35
|
Chen L: Co-inhibitory molecules of the
B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol.
4:336–347. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zang X and Allison JP: The B7 family and
cancer therapy: Costimulation and coinhibition. Clin Cancer Res.
13:5271–5279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Choi IH, Zhu G, Sica GL, Strome SE,
Cheville JC, Lau JS, Zhu Y, Flies DB, Tamada K and Chen L: Genomic
organization and expression analysis of B7-H4, an immune inhibitory
molecule of the B7 family. J Immunol. 171:4650–4654. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tringler B, Zhuo S, Pilkington G, Torkko
KC, Singh M, Lucia MS, Heinz DE, Papkoff J and Shroyer KR: B7-h4 is
highly expressed in ductal and lobular breast cancer. Clin Cancer
Res. 11:1842–1848. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tringler B, Liu W, Corral L, Torkko KC,
Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J and Shroyer
KR: B7-H4 overexpression in ovarian tumors. Gynecol Oncol.
100:44–52. 2006. View Article : Google Scholar
|
|
40
|
Miyatake T, Tringler B, Liu W, Liu SH,
Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A and Shroyer KR:
B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid
adenocarcinomas and inversely correlated with tumor T-cell
infiltration. Gynecol Oncol. 106:119–127. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Small EJ, Tchekmedyian NS, Rini BI, Fong
L, Lowy I and Allison JP: A pilot trial of CTLA-4 blockade with
human anti-CTLA-4 in patients with hormone-refractory prostate
cancer. Clin Cancer Res. 13:1810–1815. 2007. View Article : Google Scholar : PubMed/NCBI
|
